JavaScript seem to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.
Research Grade Coltuximab is a chimeric monoclonal antibody which targets Blymphocyte antigen CD19. Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent. This product is only the monoclonal antibody, without the drug conjugated.